Production and enhanced anti-tumor activity of tumor necrosis factor in mice treated with cyclophosphamide.

[Drug interaction of antitumor drugs. II. Antitumor activity of cyclophosphamide in immunopotentiator-treated mice (author's transl)].

CD40 ligand-engineered mesenchymal stem cells greatly enhanced the antitumor immune response and lifespan in mice.

Endogenous production of tumor necrosis factor in normal mice orally treated with Deodan--a preparation from Lactobacillus bulgaricus "LB51".

Acute Brucella melitensis M16 infection model in mice treated with tumor necrosis factor-alpha inhibitors.

Neopterin augmentation of tumor necrosis factor production.

Tumor necrosis factor production in patients with leprosy.

Tumor necrosis factor alpha mediates lethal activity of killed gram-negative and gram-positive bacteria in D-galactosamine-treated mice.

Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302).

Anti-tumor necrosis factor receptor and tumor necrosis factor agonist activity by an anti-idiotypic antibody.

Interleukin-6 is a better marker of lethality than tumor necrosis factor in endotoxin treated mice.

Endothelial dysfunction in tristetraprolin-deficient mice is not caused by enhanced tumor necrosis factor-α expression.

Enhancement of lipopolysaccharide-induced tumor necrosis factor production in mice by carrageenan pretreatment.

Production of tumor necrosis factor alpha and interferon gamma in interleukin-2-treated melanoma patients: correlation with clinical toxicity.

Enhanced tumor necrosis factor alpha in coronavirus but not in paracetamol-induced acute hepatic necrosis in mice.

Platelet-activating factor augments tumor necrosis factor and procoagulant activity.

Dehydroepiandrosterone protects mice from endotoxin toxicity and reduces tumor necrosis factor production.

Q Fever Risk in Patients Treated with Chronic Antitumor Necrosis Factor-Alpha Therapy.

Tumor necrosis factor, tumor necrosis factor inhibition, and cancer risk.

Systemic tumor necrosis factor-alpha production in experimental colitis.

Inhibition by perilla juice of tumor necrosis factor production.

Post-translational processing of tumor necrosis factor production.

Lipopolysaccharide-induced production of tumor necrosis factor activity in rats with and without risk factors for stroke.

Disease activity improvement in rheumatoid arthritis treated with tumor necrosis factor-α inhibitors correlates with increased soluble Fas levels.

The risk of tuberculosis in patients with psoriasis treated with anti-tumor necrosis factor agents.

Suggest Documents

[Drug interaction of antitumor drugs. II. Antitumor activity of cyclophosphamide in immunopotentiator-treated mice (author's transl)].

CD40 ligand-engineered mesenchymal stem cells greatly enhanced the antitumor immune response and lifespan in mice.

Endogenous production of tumor necrosis factor in normal mice orally treated with Deodan--a preparation from Lactobacillus bulgaricus "LB51".

Acute Brucella melitensis M16 infection model in mice treated with tumor necrosis factor-alpha inhibitors.

Neopterin augmentation of tumor necrosis factor production.

Tumor necrosis factor production in patients with leprosy.

Tumor necrosis factor alpha mediates lethal activity of killed gram-negative and gram-positive bacteria in D-galactosamine-treated mice.

Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302).

Anti-tumor necrosis factor receptor and tumor necrosis factor agonist activity by an anti-idiotypic antibody.

Interleukin-6 is a better marker of lethality than tumor necrosis factor in endotoxin treated mice.

Endothelial dysfunction in tristetraprolin-deficient mice is not caused by enhanced tumor necrosis factor-α expression.

Enhancement of lipopolysaccharide-induced tumor necrosis factor production in mice by carrageenan pretreatment.

Production of tumor necrosis factor alpha and interferon gamma in interleukin-2-treated melanoma patients: correlation with clinical toxicity.

Enhanced tumor necrosis factor alpha in coronavirus but not in paracetamol-induced acute hepatic necrosis in mice.

Platelet-activating factor augments tumor necrosis factor and procoagulant activity.

Dehydroepiandrosterone protects mice from endotoxin toxicity and reduces tumor necrosis factor production.

Q Fever Risk in Patients Treated with Chronic Antitumor Necrosis Factor-Alpha Therapy.

Tumor necrosis factor, tumor necrosis factor inhibition, and cancer risk.

Systemic tumor necrosis factor-alpha production in experimental colitis.

Inhibition by perilla juice of tumor necrosis factor production.

Post-translational processing of tumor necrosis factor production.

Lipopolysaccharide-induced production of tumor necrosis factor activity in rats with and without risk factors for stroke.

Disease activity improvement in rheumatoid arthritis treated with tumor necrosis factor-α inhibitors correlates with increased soluble Fas levels.

The risk of tuberculosis in patients with psoriasis treated with anti-tumor necrosis factor agents.

Production and enhanced anti-tumor activity of tumor necrosis factor in mice treated with cyclophosphamide.

Recommend Documents

Follow Us